Drugs / Levosimendan
Levosimendan
also known as
SIMDAX · LEVO · ODM-109 · Simdax (manufacturer: Orion Corporation) · SIMDAX (trade mark) · SimdaxTM · Sindax
Trials 57 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 30 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01576094 Comparator | Nov 2009 → Nov 2010 | — | Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05063370 Comparator | Aug → Dec 2021 | heart failure | Ain Shams University | Unknown | No outcome recorded |
| Phase 2 | NCT03557255 Comparator | Aug 2017 → Feb 2018 | heart failure | National Cancer Institute, Egypt | Completed | No outcome recorded |
| Phase 2 | NCT01120106 Comparator | Jan 2009 → Dec 2010 | — | Bambino Gesù Hospital and Research Institute | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT07288398 Comparator | Mar 2026 → Jun 2028 expected | pulmonary hypertension | Tenax Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06478667 Comparator | Dec 2024 → Jan 2025 | acute myocarditis | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT04329624 Comparator | Oct 2020 → Nov 2023 | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase 3 | NCT02133105 Comparator | Apr 2014 → May 2017 | cardio-renal syndrome | Göteborg University | Completed | No outcome recorded |
| Phase 3 | NCT02184819 Comparator | Jun 2013 → Jun 2015 | left ventricular failure | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 415 trials | ||||||
| Phase 4 | NCT07105202 Comparator | Sep 2025 → Aug 2027 expected | — | Radboud University Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT04330755 Comparator | Feb 2021 → Mar 2023 | aorta coarctation | Dalia Saad Abd-El Kader | Completed | No outcome recorded |
| Phase 4 | NCT03576677 Comparator | Aug 2019 → Jul 2020 | heart failure | Finn Gustafsson | Unknown | No outcome recorded |
| Phase 4 | NCT01500785 Comparator | Jun → Dec 2018 | myocardial stunning | Tampere University Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT02640846 Comparator | Dec 2015 → Jan 2019 | cardiomyopathy, infectious disease with sepsis | Sahlgrenska University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02531724 Comparator | Sep 2015 → Dec 2020 | acute kidney injury | Sahlgrenska University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02012946 Comparator | Dec 2013 | cardiovascular disorder | Azienda Policlinico Umberto I | Unknown | No outcome recorded |
| Phase 4 | NCT02261948 Comparator | Sep 2012 → Sep 2014 | heart failure | Centro Cardiologico Monzino | Completed | No outcome recorded |
| Phase 4 | NCT01616069 Comparator | Feb 2012 | — | Federal University of Juiz de Fora | Completed | No outcome recorded |
| Phase 4 | NCT01022983 Comparator | Apr 2011 → Dec 2012 | heart failure | Sykehuset i Vestfold HF | Withdrawn | No outcome recorded |
| Phase 4 | NCT01318460 Comparator | Mar 2011 → Mar 2014 | coronary artery disorder | AHEPA University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01536132 Comparator | Apr 2010 → Oct 2013 | heart failure | Parc de Salut Mar | Completed | No outcome recorded |
| Phase 4 | NCT00988806 Comparator | Nov 2009 → Dec 2013 | advanced heart failure | Hospital Universitario de Canarias | Unknown | No outcome recorded |
| Phase 4 | NCT01969071 Comparator | Jul 2009 → Jan 2013 | mitral valve disorder | Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00324766 Comparator | Jun 2006 → Sep 2011 | cardiogenic shock, heart failure, myocardial infarction | Oslo University Hospital | Completed | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT07664748 Background | Jun 2026 → May 2027 expected | heart failure | Niguarda Hospital | Not yet recruiting | No outcome recorded |
| — | NCT04718350 Comparator | Jan 2021 → Dec 2023 | heart failure, pulmonary hypertension | Aretaieion University Hospital | Completed | No outcome recorded |
| — | NCT04599816 Comparator | Oct 2020 → Oct 2022 | heart failure, pulmonary hypertension | Aretaieion University Hospital | Completed | No outcome recorded |
| — | NCT03022877 Comparator | Jun 2017 → Dec 2018 | myocardial infarction | RWTH Aachen University | Withdrawn | No outcome recorded |
| — | NCT01101620 Comparator | Apr → Sep 2010 | — | University Medical Center Nijmegen | Completed | No outcome recorded |
| — | NCT01221116 Comparator | Jan 2003 → Dec 2008 | heart failure | Ullevaal University Hospital | Terminated | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 89 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Levosimendan | “Levosimendan, an inotropic agent, enhances cardiac contractility through calcium sensitization with minimal oxygen demand and, in turn, decreases the risk of arrhythmia.” NCT06478667 ↗84“Effects of Levosimendan on Cardiac Function After TAVR in Patients With Heart Failure” NCT06196177 ↗ “study drug, levosimendan (given orally)” NCT07288398 ↗ “Levosimendan” NCT05658692 ↗ |
| Known as | LEVO | “Levosimendan (LEVO) is a novel class IND developed for the treatment of heart failure.” NCT01576094 ↗ |
| Known as | ODM-109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02487407 ↗ |
| Known as | SIMDAX | “Levosimendan (SIMDAX) is a new calcium sensitizer which increases the myocardial contractility without particular promotion of the intracellular calcium accumulation.” NCT01318460 ↗ |
| Known as | Simdax (manufacturer: Orion Corporation) | “Simdax (manufacturer: Orion Corporation)” NCT01500785 ↗ |
| Known as | SIMDAX (trade mark) | “SIMDAX (trade mark)” NCT01536132 ↗ |
| Known as | SimdaxTM | “Levosimendan (SimdaxTM, Abbott Laboratories, Abbott Park, IL) is a calcium sensitizer which has been shown to have beneficial hemodynamic effects in patients with decompensated...” NCT00585104 ↗ |
| Known as | Sindax | “The Spanish Randomized Clinical Trial on Levosimendan (brand name: Sindax) (SPARTANS) aims to demonstrate the effectiveness of the preoperative use of Levosimendan in reducing...” NCT04179604 ↗ |
| Action | Activate | “mediated via the opening of sarcolemmal and mitochondrial ATP-sensitive potassium channels” PMID 19151048 ↗ Feb 2009 |
| Modality | Other / unclassified | “Levosimendan (SimdaxTM, Abbott Laboratories, Abbott Park, IL) is a calcium sensitizer” NCT00585104 ↗ |
| Route | Intravenous | “given intravenously” PMID 24621834 ↗ Apr 2013 |